RES4-22 Inhibitors
RES4-22 inhibitors belong to a class of chemical compounds that are designed to interact with specific biological molecules. The designation "RES4-22" likely refers to a particular target or a key characteristic of the molecule's structure or function, which is a common convention in biochemical nomenclature. These inhibitors function by binding to their target with high affinity, thereby altering its activity. The target could be an enzyme, a receptor, or any other protein that plays a critical role in a biochemical pathway. The inhibition process usually involves the compound mimicking the natural substrate or ligand of the protein, fitting into its active site or ligand-binding domain and preventing the normal interaction that would occur with the physiological substrates or ligands.
The development of RES4-22 inhibitors would typically be the result of extensive research into the structure-activity relationships (SAR) governing the interaction between the inhibitor and its target. This entails a deep understanding of the molecular makeup of the target site and the way in which inhibitors can influence its function. Chemists would synthesize a variety of compounds with different substituents and functional groups to determine the molecular framework that results in the most effective inhibition. Advanced techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling might be employed to elucidate the precise manner in which these inhibitors engage with their targets and to design more potent inhibitors. Stability, solubility, and specificity are key factors that are refined during the development of RES4-22 inhibitors to ensure that they effectively and selectively interact with their intended target without affecting other proteins or pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 can indirectly lead to the inhibition of the RES4-22 protein if it is downstream of PI3K signaling. By blocking PI3K, this compound prevents the phosphorylation and activation of AKT, which may be necessary for RES4-22 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a selective inhibitor of mitogen-activated protein kinase kinase (MEK), PD98059 blocks the MAPK/ERK pathway. If RES4-22 is regulated by ERK signaling, PD98059's inhibition of MEK could indirectly decrease RES4-22's functional activity by preventing its phosphorylation or activation by ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. If RES4-22 is activated by p38 MAPK-mediated signaling, SB203580 would indirectly inhibit RES4-22 by blocking the kinase activity of p38 MAPK and thereby reducing its phosphorylation or activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 could inhibit RES4-22 if JNK signaling is required for its activation. By inhibiting JNK, SP600125 may prevent the phosphorylation of transcription factors that regulate RES4-22 expression or activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can potentially inhibit RES4-22 if mTOR signaling is involved in its activation. By inhibiting mTOR, rapamycin would decrease the activity of downstream effectors that may play a role in the activation of RES4-22. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective NUAK1 inhibitor. If RES4-22 is activated by NUAK1-mediated pathways, this compound would lead to the inhibition of RES4-22 by preventing NUAK1 from phosphorylating its substrates, which could be involved in the activation of RES4-22. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $220.00 $378.00 | 5 | |
BIX 02189 is an inhibitor of MEK5, which is part of the MAPK7 signaling pathway. If RES4-22 is a downstream target of this pathway, BIX 02189 would inhibit RES4-22 by blocking the MEK5-mediated activation. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
This compound acts as an inhibitor of BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. If RES4-22 functions downstream of BMP signaling, Dorsomorphin could inhibit RES4-22 activity by blocking BMP-mediated transcriptional events. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go6983 is a pan-protein kinase C (PKC) inhibitor. If RES4-22 is activated by PKC-mediated phosphorylation, Go6983 would inhibit RES4-22 by preventing its activation by PKC isoforms. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
This compound is a selective inhibitor of the Rho-associated, coiled-coil containing protein kinase (ROCK). If RES4-22 is regulated by ROCK signaling, Y-27632 would lead to the inhibition of RES4-22 by preventing the phosphorylation and activation of downstream targets of ROCK that may involve RES4-22. | ||||||